Literature DB >> 11713128

Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997.

M Bashar1, P Alcabes, W N Rom, R Condos.   

Abstract

STUDY
OBJECTIVES: To investigate the characteristics of tuberculosis infection in diabetic patients at Bellevue Hospital.
DESIGN: We conducted a case-control study retrospectively reviewing the records of patients at Bellevue Hospital Center from 1987 to 1997 with a discharge diagnosis of tuberculosis and diabetes mellitus.
SETTING: Bellevue Hospital Center is a 1,200-bed, inner-city municipal hospital located in the Lower East Side of New York City. PATIENTS: Fifty-three identified patients had verified tuberculosis infection and diabetes; of these, 50 charts were available for review. One hundred five control cases were selected from nondiabetic patients with a discharge diagnosis of tuberculosis during the same time period. MEASUREMENTS AND
RESULTS: Thirty-six percent (18 cases) of the patients with diabetes and tuberculosis had multidrug-resistant tuberculosis (MDR-TB) compared to only 10% (10 cases) in the control group (p < 0.01) Controlling for homelessness, HIV status, and directly observed therapy, the relative risk of MDR-TB was calculated to be 8.6 (confidence interval, 3.1 to 23.6) in the diabetic group compared to the control group.
CONCLUSIONS: There was a significant association between diabetes and MDR-TB. Diabetes continues to be a risk factor for tuberculosis and was associated with MDR-TB in our patients.

Entities:  

Mesh:

Year:  2001        PMID: 11713128     DOI: 10.1378/chest.120.5.1514

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  42 in total

Review 1.  Diabetes and Tuberculosis.

Authors:  Blanca I Restrepo
Journal:  Microbiol Spectr       Date:  2016-12

2.  Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances.

Authors:  Blanca I Restrepo
Journal:  Clin Infect Dis       Date:  2007-07-05       Impact factor: 9.079

Review 3.  Population causes and consequences of leading chronic diseases: a comparative analysis of prevailing explanations.

Authors:  David Stuckler
Journal:  Milbank Q       Date:  2008-06       Impact factor: 4.911

Review 4.  Tuberculosis and diabetes mellitus: convergence of two epidemics.

Authors:  Kelly E Dooley; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

5.  Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru.

Authors:  M J Magee; E Bloss; S S Shin; C Contreras; H Arbanil Huaman; J Calderon Ticona; J Bayona; C Bonilla; M Yagui; O Jave; J P Cegielski
Journal:  Int J Infect Dis       Date:  2013-02-22       Impact factor: 3.623

6.  Degradation of myxovirus virion RNA by periodate.

Authors:  G A Tannock; I P Griffith
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

7.  A nested case-control study on relapse predictors among tuberculosis patients treated in Yemen's NTCP.

Authors:  M S Anaam; M I M Ibrahim; A W Al Serouri; A Bassili; A Aldobhani
Journal:  Public Health Action       Date:  2012-12-21

8.  Convergence of tuberculosis and diabetes mellitus: time to individualise pharmaceutical care.

Authors:  Shubashini Gnanasan; Kang Nee Ting; Kok Thong Wong; Salmiah Mohd Ali; Abdul Razak Muttalif; Claire Anderson
Journal:  Int J Clin Pharm       Date:  2011-01-14

9.  Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.

Authors:  A K Hemanth Kumar; V Chandrasekaran; T Kannan; A Lakshmi Murali; J Lavanya; V Sudha; Soumya Swaminathan; Geetha Ramachandran
Journal:  Eur J Clin Pharmacol       Date:  2016-09-20       Impact factor: 2.953

Review 10.  Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  James C Johnston; Neal C Shahidi; Mohsen Sadatsafavi; J Mark Fitzgerald
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.